CXCR2 and neoplasm: The terminally mature N2 subset (CD10+CD16brightCD101+), marked by high CXCR2 expression, generated the strongest ROS response; however, its frequency declined in advanced disease, indicating depletion of mature neutrophils in an inhospitable tumour milieu (135, 140).